Frontiers in Endocrinology (Sep 2024)

Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report

  • Catarina Cidade-Rodrigues,
  • Ana Paula Santos,
  • Ana Paula Santos,
  • Raquel Calheiros,
  • Sara Santos,
  • Catarina Matos,
  • Ana Paula Moreira,
  • Isabel Inácio,
  • Pedro Souteiro,
  • Joana Oliveira,
  • Manuel Jácome,
  • Sofia S. Pereira,
  • Sofia S. Pereira,
  • Rui Henrique,
  • Rui Henrique,
  • Rui Henrique,
  • Isabel Torres,
  • Mariana P. Monteiro,
  • Mariana P. Monteiro

DOI
https://doi.org/10.3389/fendo.2024.1405835
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionAlpha-cell hyperplasia (ACH) is a rare pancreatic endocrine condition. Three types of ACH have been described: functional or nonglucagonoma hyperglucagonemic glucagonoma syndrome, reactive or secondary to defective glucagon signaling, and non-functional. Few cases of ACH with concomitant pancreatic neuroendocrine tumors (pNETs) have been reported and its etiology remains poorly understood. A case report of non-functional ACH with glucagon-producing NET is herein presented.Case reportA 72-year-old male was referred to our institution for a 2 cm single pNET incidentally found during imaging for acute cholecystitis. The patient’s past medical history included type 2 diabetes (T2D) diagnosed 12 years earlier, for which he was prescribed metformin, dapagliflozin, and semaglutide. The pNET was clinically and biochemically non-functioning, apart from mildly elevated glucagon 217 pg/ml (<209), and 68Ga-SSTR PET/CT positive uptake was only found at the pancreatic tail (SUVmax 11.45). The patient underwent a caudal pancreatectomy and the post-operative 68Ga-SSTR PET/CT was negative. A multifocal well-differentiated NET G1, pT1N0M0R0 (mf) strongly staining for glucagon on a background neuroendocrine alpha-cell hyperplasia with some degree of acinar fibrosis was identified on pathology analysis.Discussion and conclusionThis case reports the incidental finding of a clinically non-functioning pNET in a patient with T2D and elevated glucagon levels, unexpectedly diagnosed as glucagon-producing NET and ACH. A high level of suspicion was required to conduct the glucagon immunostaining, which is not part of the pathology routine for a clinically non-functioning pNET, and was key for the diagnosis that otherwise would have been missed. This case highlights the need to consider the diagnosis of glucagon-producing pNET on an ACH background even in the absence of glucagonoma syndrome.

Keywords